The study was performed at Charles River, Tranent, Edinburgh, UK. The animals were approximately seven weeks old at treatment start and were in the weight range of 179-229 g (males) and 109-162 g

(females). Animals were randomized to cages on racks separated by treatment group and sex and housed in the same room. Control and krill powder groups were housed on separate racks with two to three animals per cage. Rats were given food and water (domestic mains water) ad libitum during this period, and were provided with wooden chew sticks for environmental enrichment (Tapvei Estonia OÜ, Harjumma, Estonia). The animals were kept at 19-23 °C, 40-70% humidity and a fixed light cycle (light hours were from 7 to 19 h) throughout the study period. The study was conducted in accordance with the OECD Principles of Good Laboratory Practice (GLP) as incorporated into the United Kingdom Statutory Instrument for GLP, and as accepted by regulatory authorities throughout Osimertinib clinical trial the European Community, United States (FDA and EPA) and Japan (MHLW, MAFF and METI). Two groups of ten male

and ten female Han Wistar rats were fed diets containing a total of 8% oil for a period of 13 weeks. The control diet was supplemented with 8% soya bean oil. The krill powder diet was incorporated with 9.67% krill powder (corresponding to 5% krill oil). The krill powder contained 20.2% PL, 51.7% total lipids, Raf pathway 41.7% proteins and 115.5 mg/kg astaxanthin (for more details see Table 1), and the amounts of soy bean oil (3%) and casein added to the krill powder diet were reduced in such a way that the lipid content and protein content were the same in the two test diets. This amount of krill powder is equal to inclusion of 5% krill oil, which corresponds to 2.5 – 5 g/kg of body weight. After conversion to human equivalent doses (HED), the studied dose range provides 6-phosphogluconolactonase a 24- to 48-fold safety margin with the recommended supplement level of 1 g/day. The diets were based on the standard RM1 diet (http://www.sdsdiets.com/pdfs/RM1P-E-FG.pdf) and prepared by Special Diet Services (Witham,

UK) according to their in-house standard operating procedures. The krill powder diet was verified for homogeneity by Nofima AS (Bergen, Norway). After inclusion of krill powder into the final diet form, the recovery of EPA and DHA was 97.0 ± 0.7% and 96.8 ± 0.7%, respectively. The measurements were performed at the beginning of the study and the homogeneity was verified by measuring EPA and DHA in 3 samples of the krill powder diet. Both diets were stored at -20 °C to ensure stability of the feed until given to the animals on a daily discard and top-up routine. Every day during the study the well-being and reaction to treatment of the animals was monitored and once each week the animals received a detailed clinical examination. The eyes of the animals were examined before, during and at the end of the experiment.